U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C14H11Cl2NO2
Molecular Weight 296.149
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of DICLOFENAC

SMILES

c1ccc(c(c1)CC(=O)O)Nc2c(cccc2Cl)Cl

InChI

InChIKey=DCOPUUMXTXDBNB-UHFFFAOYSA-N
InChI=1S/C14H11Cl2NO2/c15-10-5-3-6-11(16)14(10)17-12-7-2-1-4-9(12)8-13(18)19/h1-7,17H,8H2,(H,18,19)

HIDE SMILES / InChI

Molecular Formula C14H11Cl2NO2
Molecular Weight 296.149
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment:: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/25963327 | https://www.ncbi.nlm.nih.gov/pubmed/20470236 | http://www.pharmaceutical-journal.com/news-and-analysis/news/diclofenac-a-useful-drug-that-may-now-be-entering-its-twilight-years/11121261.article

Diclofenac is a nonsteroidal anti-inflammatory drug (NSAID) of the phenylacetic acid class with anti-inflammatory, analgesic, and antipyretic properties. Contrary to the action of many traditional NSAIDs, diclofenac inhibits cyclooxygenase (COX)-2 enzyme with greater potency than it does COX-1. In addition diclofenac can inhibit the thromboxane-prostanoid receptor, affect arachidonic acid release and uptake, inhibit lipoxygenase enzymes, and activate the nitric oxide-cGMP antinociceptive pathway. Other novel mechanisms of action may include the inhibition of substrate P, inhibition of peroxisome proliferator activated receptor gamma (PPARgamma), blockage of acid-sensing ion channels, alteration of interleukin-6 production, and inhibition of N-methyl-D-aspartate (NMDA) receptor hyperalgesia. Similar to other NSAIDs, diclofenac is associated with serious dose-dependent gastrointestinal, cardiovascular, and renal adverse effects. Since its introduction in 1973, a number of different diclofenac-containing drug products have been developed with the goal of improving efficacy, tolerability, and patient convenience. Delayed- and extended-release forms of diclofenac sodium were initially developed with the goal of improving the safety profile of diclofenac and providing convenient, once-daily dosing for the treatment of patients with chronic pain. New drug products consisting of diclofenac potassium salt were associated with faster absorption and rapid onset of pain relief. These include diclofenac potassium immediate-release tablets, diclofenac potassium liquid-filled soft gel capsules, and diclofenac potassium powder for oral solution. The advent of topical formulations of diclofenac enabled local treatment of pain and inflammation while minimizing systemic absorption of diclofenac. SoluMatrix diclofenac, consisting of submicron particles of diclofenac free acid and a proprietary combination of excipients, was developed to provide analgesic efficacy at reduced doses associated with lower systemic absorption. The drug's likely impact on the Asian vulture population was widely reported. The dramatic mortality was attributed largely to renal failure caused by exposure to diclofenac in livestock carcasses on which the birds fed. Although not the most endearing species, vultures are important environmental scavengers and, since veterinary use of diclofenac was stopped in the region in 2006, the decline in vulture numbers has slowed.

Originator

Curator's Comment:: reference retrieved from http://www.pharmaceutical-journal.com/news-and-analysis/news/diclofenac-a-useful-drug-that-may-now-be-entering-its-twilight-years/11121261.article

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
DICLOFENAC SODIUM

Approved Use

Diclofenac Sodium Extended-release Tablets are indicated: •For relief of the signs and symptoms of osteoarthritis •For relief of the signs and symptoms of rheumatoid arthritis
Primary
DICLOFENAC SODIUM

Approved Use

Diclofenac Sodium Extended-release Tablets are indicated: •For relief of the signs and symptoms of osteoarthritis •For relief of the signs and symptoms of rheumatoid arthritis
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
902 ng/mL
50 mg 3 times / day steady-state, oral
dose: 50 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
DICLOFENAC plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
302 ng/mL
12.5 mg 3 times / day steady-state, oral
dose: 12.5 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
DICLOFENAC plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
749 ng/mL
25 mg 3 times / day steady-state, oral
dose: 25 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
DICLOFENAC plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
1208 ng × h/mL
50 mg 3 times / day steady-state, oral
dose: 50 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
DICLOFENAC plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
319 ng × h/mL
12.5 mg 3 times / day steady-state, oral
dose: 12.5 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
DICLOFENAC plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
609 ng × h/mL
25 mg 3 times / day steady-state, oral
dose: 25 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
DICLOFENAC plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
1.64 h
50 mg 3 times / day steady-state, oral
dose: 50 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
DICLOFENAC plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
1.19 h
12.5 mg 3 times / day steady-state, oral
dose: 12.5 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
DICLOFENAC plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
1.87 h
25 mg 3 times / day steady-state, oral
dose: 25 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
DICLOFENAC plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
2.3 h
unknown, oral
DICLOFENAC serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
1%
unknown, oral
DICLOFENAC serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
75 mg/mL single, intravenous
Dose: 75 mg/mL
Route: intravenous
Route: single
Dose: 75 mg/mL
Sources:
healthy, 18 - 53 years
Health Status: healthy
Age Group: 18 - 53 years
Sex: M+F
Sources:
50 mg single, oral
Dose: 50 mg
Route: oral
Route: single
Dose: 50 mg
Sources:
healthy, 21-51 years
n = 24
Health Status: healthy
Age Group: 21-51 years
Sex: M+F
Population Size: 24
Sources:
Other AEs: Nephrotoxicity...
Other AEs:
Nephrotoxicity
Sources:
500 mg single, oral
Overdose
Dose: 500 mg
Route: oral
Route: single
Dose: 500 mg
Sources:
unknown, adult
Health Status: unknown
Age Group: adult
Sex: unknown
Sources:
Disc. AE: Drowsiness, Lethargy...
AEs leading to
discontinuation/dose reduction:
Drowsiness
Lethargy
Nausea
Vomiting
Epigastric pain
Sources:
AEs

AEs

AESignificanceDosePopulation
Nephrotoxicity
50 mg single, oral
Dose: 50 mg
Route: oral
Route: single
Dose: 50 mg
Sources:
healthy, 21-51 years
n = 24
Health Status: healthy
Age Group: 21-51 years
Sex: M+F
Population Size: 24
Sources:
Drowsiness Disc. AE
500 mg single, oral
Overdose
Dose: 500 mg
Route: oral
Route: single
Dose: 500 mg
Sources:
unknown, adult
Health Status: unknown
Age Group: adult
Sex: unknown
Sources:
Epigastric pain Disc. AE
500 mg single, oral
Overdose
Dose: 500 mg
Route: oral
Route: single
Dose: 500 mg
Sources:
unknown, adult
Health Status: unknown
Age Group: adult
Sex: unknown
Sources:
Lethargy Disc. AE
500 mg single, oral
Overdose
Dose: 500 mg
Route: oral
Route: single
Dose: 500 mg
Sources:
unknown, adult
Health Status: unknown
Age Group: adult
Sex: unknown
Sources:
Nausea Disc. AE
500 mg single, oral
Overdose
Dose: 500 mg
Route: oral
Route: single
Dose: 500 mg
Sources:
unknown, adult
Health Status: unknown
Age Group: adult
Sex: unknown
Sources:
Vomiting Disc. AE
500 mg single, oral
Overdose
Dose: 500 mg
Route: oral
Route: single
Dose: 500 mg
Sources:
unknown, adult
Health Status: unknown
Age Group: adult
Sex: unknown
Sources:
OverviewDrug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
moderate
no
no
no
no
strong
weak
weak
weak
yes [Ki 11 uM]
yes [Ki 19 uM]
yes [Ki 28 uM]
yes [Ki 52 uM]
yes [Ki 60 uM]
yes
yes
yes
yes
yes
yes
yes
yes
yes
yes
yes
yes
yes
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
major
minor
minor
minor
moderate
no
no
no
no
no
no
no
no
no
no
no
yes
yes
yes
yes
yes
yes
yes
yes
yes
yes
yes
yes
yes
yes
yes
yes
Tox targets

Tox targets

PubMed

PubMed

TitleDatePubMed
Nimesulide, a balanced drug for the treatment of osteoarthritis.
2001
Celecoxib versus diclofenac in the management of osteoarthritis of the knee.
2001
Risk of upper gastrointestinal bleeding and perforation associated with low-dose aspirin as plain and enteric-coated formulations.
2001
Review: uveitis and immunosuppressive drugs.
2001 Apr
Cataflam-induced esophageal ulceration.
2001 Apr
Anti-inflammatory drugs. IX. Hydrated diethylammonium (2-(2,6-dichlorophenylamino)phenyl)acetate (HDEA.D.H2O).
2001 Apr
Efficacy of peripheral morphine analgesia in inflamed, non-inflamed and perineural tissue of dental surgery patients.
2001 Apr
Corneal complications associated with topical ophthalmic use of nonsteroidal antiinflammatory drugs.
2001 Apr
Influence of electrical and chemical factors on transdermal iontophoretic delivery of three diclofenac salts.
2001 Apr
The role of matrix metalloproteinases in ulcerative keratolysis associated with perioperative diclofenac use.
2001 Apr
Tramadol vs. diclofenac for posttonsillectomy analgesia.
2001 Apr
Inhibition of phenytoin hydroxylation in human liver microsomes by several selective serotonin re-uptake inhibitors.
2001 Apr
Equivalence of generic and brand-name ophthalmic products.
2001 Apr 1
Oil components modulate physical characteristics and function of the natural oil emulsions as drug or gene delivery system.
2001 Apr 28
Inhibition of COX in ocular tissues: an in vitro model to identify selective COX-2 inhibitors.
2001 Feb
Comparative study of diclofenac sodium and paracetamol for treatment of pain after adenotonsillectomy in children.
2001 Feb
Diclofenac-induced gastric mucosal fluorescence in rats.
2001 Feb
Determination of diclofenac sodium, flufenamic acid, indomethacin and ketoprofen by LC-APCI-MS.
2001 Feb
Bioequivalence of two aceclofenac tablet formulations after a single oral dose to healthy male Korean volunteers.
2001 Feb
Potentiation of bradykinin by angiotensin-(1-7) on arterioles of spontaneously hypertensive rats studied in vivo.
2001 Feb
Thermographic imaging of postoperative inflammation modified by anti-inflammatory pretreatment.
2001 Feb
Tacholiquine inhalation and aspirin-induced asthma.
2001 Feb
Etoricoxib (MK-0663): preclinical profile and comparison with other agents that selectively inhibit cyclooxygenase-2.
2001 Feb
Effects of anti-inflammatory drugs following cataract extraction.
2001 Feb
[Topical administration is better than oral administration].
2001 Feb 1
Translocation of drug particles in HPMC matrix gel layer: effect of drug solubility and influence on release rate.
2001 Feb 23
Micronized ethylcellulose used for designing a directly compressed time-controlled disintegration tablet.
2001 Feb 23
A comparative experimental study of the effects of diclofenac and ketoprofen on the small-bowel mucosa of canines.
2001 Jan
Truth and consequences.
2001 Jan
Truth and consequences.
2001 Jan
Effects of diclofenac in the rat tail ischaemia--reperfusion injury model of acute hyperalgesia.
2001 Jan
Preoperative rectal diclofenac versus paracetamol for tonsillectomy: effects on pain and blood loss.
2001 Jan
Effects of diclofenac or ketorolac on the inhibitory activity of cidofovir in the Ad5/NZW rabbit model.
2001 Jan
Interaction of delavirdine with human liver microsomal cytochrome P450: inhibition of CYP2C9, CYP2C19, and CYP2D6.
2001 Jan
Application of higher throughput screening (HTS) inhibition assays to evaluate the interaction of antiparasitic drugs with cytochrome P450s.
2001 Jan
Using evidence from different sources: an example using paracetamol 1000 mg plus codeine 60 mg.
2001 Jan 10
Bone-specific delivery and sustained release of diclofenac, a non-steroidal anti-inflammatory drug, via bisphosphonic prodrug based on the Osteotropic Drug Delivery System (ODDS).
2001 Jan 29
[Liver damage and nonsteroidal anti-inflammatory drugs: case non-case study in the French Pharmacovigilance Database].
2001 Jan-Feb
Is diclofenac a valuable CYP2C9 probe in humans?
2001 Jan-Feb
Analgesic effect of epidural neostigmine after abdominal hysterectomy.
2001 Mar
Perioperative intravenous flurbiprofen reduces postoperative pain after abdominal hysterectomy.
2001 Mar
Docetaxel extravasation.
2001 Mar
[Effect of tobramycin with topical diclofenac on arachidonic acid in endotoxin-induced uveitis].
2001 Mar
Physical incompatibility between atracurium and intravenous diclofenac.
2001 Mar
Enhanced disruption of the blood-aqueous barrier and the incidence of angiographic cystoid macular edema by topical timolol and its preservative in early postoperative pseudophakia.
2001 Mar
Decreased flow-dependent dilation in carotid arteries of tissue kallikrein-knockout mice.
2001 Mar 30
Keratitis, ulceration, and perforation associated with topical nonsteroidal anti-inflammatory drugs.
2001 May
Identification and characterization of human organic anion transporter 3 expressing predominantly in the kidney.
2001 May
Structure-hepatic disposition relationships for cationic drugs in isolated perfused rat livers: transmembrane exchange and cytoplasmic binding process.
2001 May
Characterization of rat and human UDP-glucuronosyltransferases responsible for the in vitro glucuronidation of diclofenac.
2001 May
Patents

Sample Use Guides

For topical dosage form (gel): For actinic keratosis using Solaraze® 3% gel: Adults—Apply to affected skin area two times a day. Children—Use and dose must be determined by your doctor. For osteoarthritis of the hands, elbows, or wrists using Voltaren® 1% gel: Adults—Apply 2 grams to the affected skin areas four times a day (a total of 8 grams each day). However, the total dose should not exceed 32 grams per day over all affected joints. Use the enclosed dosing card to measure the appropriate dose. Children—Use and dose must be determined by your doctor. For osteoarthritis of the knees, ankles, or feet using Voltaren® 1% gel: Adults—Apply 4 grams to the affected skin areas four times a day (a total of 16 grams each day). However, the total dose should not exceed 32 grams per day over all affected joints. Use the enclosed dosing card to measure the appropriate dose. Children—Use and dose must be determined by your doctor. For topical dosage form (solution): For osteoarthritis of the knee: Adults—40 drops (10 drops at a time) on each affected knee four times a day. Children—Use and dose must be determined by your doctor. For transdermal dosage form (skin patch): For acute pain: Adults—One patch applied to the painful area two times a day. Children—Use and dose must be determined by your doctor. For oral dosage form (capsules): For acute pain: Adults—18 or 35 milligrams (mg) three times a day. Children—Use and dose must be determined by your doctor. For osteoarthritis: Adults—35 milligrams (mg) three times a day. Children—Use and dose must be determined by your doctor. For oral dosage forms (delayed-release tablets, enteric-coated tablets): For ankylosing spondylitis: Adults—25 milligrams (mg) four times a day, with an extra 25 mg dose at bedtime if necessary. Children—Use and dose must be determined by your doctor. For osteoarthritis: Adults—50 milligrams (mg) two or three times a day, or 75 mg two times a day. Children—Use and dose must be determined by your doctor. For rheumatoid arthritis: Adults—50 milligrams (mg) three or four times a day, or 75 mg two times a day. Children—Use and dose must be determined by your doctor. For oral dosage form (immediate-release tablets): For osteoarthritis: Adults—50 milligrams (mg) two or three times a day. Children—Use and dose must be determined by your doctor. For pain or menstrual cramps: Adults—50 milligrams (mg) three times a day. Your doctor may direct you to take 100 mg for the first dose only. Children—Use and dose must be determined by your doctor. For rheumatoid arthritis: Adults—50 milligrams (mg) three or four times a day. Children—Use and dose must be determined by your doctor. For oral dosage form (solution): For migraine headaches: Adults—One packet (50 milligrams) as a single, one time dose. Children—Use and dose must be determined by your doctor.
Route of Administration: Other
Acute (24 h) diclofenac toxicity in a range of (10-1000 μM) concentrations was assesed in primary human hepatocytes. The chronic (9 repeated doses) toxicity at one clinically relevant and another higher concentration (6.4 and 100 μM) was also tested. Acute 24 h assessment revealed toxicity only for the highest tested concentration (1 mM). Upon repeated dose exposure, toxic effects were observed even at a low, clinically relevant concentration (6.4 μM).
Substance Class Chemical
Created
by admin
on Sat Jun 26 14:26:58 UTC 2021
Edited
by admin
on Sat Jun 26 14:26:58 UTC 2021
Record UNII
144O8QL0L1
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
DICLOFENAC
HSDB   INN   MART.   MI   USAN   VANDF   WHO-DD  
INN   USAN  
Official Name English
DICLOFENAC [MI]
Common Name English
DICLOFENAC [VANDF]
Common Name English
DICLOFENAC FREE ACID
Common Name English
ACECLOFENAC IMPURITY A [EP]
Common Name English
DICLOFENAC [HSDB]
Common Name English
DICLOFENAC [INN]
Common Name English
DICLOFENAC [ORANGE BOOK]
Common Name English
LAS-41007
Code English
LAS41007
Code English
(2-((2,6-DICHLOROPHENYL)AMINO)PHENYL)ACETIC ACID
Systematic Name English
DICLOFENAC [MART.]
Common Name English
BENZENEACETIC ACID, 2-((2,6-DICHLOROPHENYL)AMINO)-
Common Name English
DICLOFENAC [USAN]
Common Name English
DICLOFENAC [WHO-DD]
Common Name English
(O-(2,6-DICHLOROANILINO)PHENYL)ACETIC ACID
Common Name English
Classification Tree Code System Code
WHO-ATC M01AB05
Created by admin on Sat Jun 26 14:26:59 UTC 2021 , Edited by admin on Sat Jun 26 14:26:59 UTC 2021
WHO-ATC S01BC03
Created by admin on Sat Jun 26 14:26:59 UTC 2021 , Edited by admin on Sat Jun 26 14:26:59 UTC 2021
WHO-ATC S01CC01
Created by admin on Sat Jun 26 14:26:59 UTC 2021 , Edited by admin on Sat Jun 26 14:26:59 UTC 2021
CFR 21 CFR 524.590
Created by admin on Sat Jun 26 14:26:59 UTC 2021 , Edited by admin on Sat Jun 26 14:26:59 UTC 2021
WHO-ATC D11AX18
Created by admin on Sat Jun 26 14:26:59 UTC 2021 , Edited by admin on Sat Jun 26 14:26:59 UTC 2021
WHO-VATC QD11AX18
Created by admin on Sat Jun 26 14:26:59 UTC 2021 , Edited by admin on Sat Jun 26 14:26:59 UTC 2021
NDF-RT N0000175722
Created by admin on Sat Jun 26 14:26:59 UTC 2021 , Edited by admin on Sat Jun 26 14:26:59 UTC 2021
WHO-ATC M01AB55
Created by admin on Sat Jun 26 14:26:59 UTC 2021 , Edited by admin on Sat Jun 26 14:26:59 UTC 2021
LIVERTOX 297
Created by admin on Sat Jun 26 14:26:59 UTC 2021 , Edited by admin on Sat Jun 26 14:26:59 UTC 2021
WHO-VATC QM02AA15
Created by admin on Sat Jun 26 14:26:59 UTC 2021 , Edited by admin on Sat Jun 26 14:26:59 UTC 2021
WHO-VATC QS01CC01
Created by admin on Sat Jun 26 14:26:59 UTC 2021 , Edited by admin on Sat Jun 26 14:26:59 UTC 2021
WHO-ATC M02AA15
Created by admin on Sat Jun 26 14:26:59 UTC 2021 , Edited by admin on Sat Jun 26 14:26:59 UTC 2021
WHO-VATC QM01AB05
Created by admin on Sat Jun 26 14:26:59 UTC 2021 , Edited by admin on Sat Jun 26 14:26:59 UTC 2021
WHO-VATC QS01BC03
Created by admin on Sat Jun 26 14:26:59 UTC 2021 , Edited by admin on Sat Jun 26 14:26:59 UTC 2021
NCI_THESAURUS C1323
Created by admin on Sat Jun 26 14:26:59 UTC 2021 , Edited by admin on Sat Jun 26 14:26:59 UTC 2021
Code System Code Type Description
DRUG BANK
DB00586
Created by admin on Sat Jun 26 14:26:59 UTC 2021 , Edited by admin on Sat Jun 26 14:26:59 UTC 2021
PRIMARY
DRUG CENTRAL
865
Created by admin on Sat Jun 26 14:26:59 UTC 2021 , Edited by admin on Sat Jun 26 14:26:59 UTC 2021
PRIMARY
HSDB
7234
Created by admin on Sat Jun 26 14:26:59 UTC 2021 , Edited by admin on Sat Jun 26 14:26:59 UTC 2021
PRIMARY
RXCUI
3355
Created by admin on Sat Jun 26 14:26:59 UTC 2021 , Edited by admin on Sat Jun 26 14:26:59 UTC 2021
PRIMARY RxNorm
INN
3270
Created by admin on Sat Jun 26 14:26:59 UTC 2021 , Edited by admin on Sat Jun 26 14:26:59 UTC 2021
PRIMARY
LACTMED
Diclofenac
Created by admin on Sat Jun 26 14:26:59 UTC 2021 , Edited by admin on Sat Jun 26 14:26:59 UTC 2021
PRIMARY
MESH
D004008
Created by admin on Sat Jun 26 14:26:59 UTC 2021 , Edited by admin on Sat Jun 26 14:26:59 UTC 2021
PRIMARY
EPA CompTox
15307-86-5
Created by admin on Sat Jun 26 14:26:59 UTC 2021 , Edited by admin on Sat Jun 26 14:26:59 UTC 2021
PRIMARY
CAS
15307-86-5
Created by admin on Sat Jun 26 14:26:59 UTC 2021 , Edited by admin on Sat Jun 26 14:26:59 UTC 2021
PRIMARY
ChEMBL
CHEMBL139
Created by admin on Sat Jun 26 14:26:59 UTC 2021 , Edited by admin on Sat Jun 26 14:26:59 UTC 2021
PRIMARY
FDA UNII
144O8QL0L1
Created by admin on Sat Jun 26 14:26:59 UTC 2021 , Edited by admin on Sat Jun 26 14:26:59 UTC 2021
PRIMARY
WIKIPEDIA
DICLOFENAC
Created by admin on Sat Jun 26 14:26:59 UTC 2021 , Edited by admin on Sat Jun 26 14:26:59 UTC 2021
PRIMARY
MERCK INDEX
M4361
Created by admin on Sat Jun 26 14:26:59 UTC 2021 , Edited by admin on Sat Jun 26 14:26:59 UTC 2021
PRIMARY Merck Index
EVMPD
SUB07092MIG
Created by admin on Sat Jun 26 14:26:59 UTC 2021 , Edited by admin on Sat Jun 26 14:26:59 UTC 2021
PRIMARY
ECHA (EC/EINECS)
239-348-5
Created by admin on Sat Jun 26 14:26:59 UTC 2021 , Edited by admin on Sat Jun 26 14:26:59 UTC 2021
PRIMARY
PUBCHEM
3033
Created by admin on Sat Jun 26 14:26:59 UTC 2021 , Edited by admin on Sat Jun 26 14:26:59 UTC 2021
PRIMARY
IUPHAR
2714
Created by admin on Sat Jun 26 14:26:59 UTC 2021 , Edited by admin on Sat Jun 26 14:26:59 UTC 2021
PRIMARY
NCI_THESAURUS
C28985
Created by admin on Sat Jun 26 14:26:59 UTC 2021 , Edited by admin on Sat Jun 26 14:26:59 UTC 2021
PRIMARY
Related Record Type Details
METABOLIC ENZYME -> SUBSTRATE
TRANSPORTER -> INHIBITOR
METABOLIC ENZYME -> INHIBITOR
POTENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
TRANSPORTER -> INHIBITOR
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
METABOLIC ENZYME -> SUBSTRATE
POTENT
TRANSPORTER -> INHIBITOR
SALT/SOLVATE -> PARENT
TRANSPORTER -> INHIBITOR
Related Record Type Details
METABOLITE -> PARENT
MINOR
METABOLITE -> PARENT
CYP3A4 is responsible for the formation of minor metabolites, 5-hydroxy and 3'-hydroxy-diclofenac
MINOR
METABOLITE -> PARENT
CYP3A4 is responsible for the formation of minor metabolites, 5-hydroxy and 3'-hydroxy-diclofenac
MINOR
PRODRUG -> METABOLITE ACTIVE
METABOLITE -> PARENT
METABOLITE LESS ACTIVE -> PARENT
MAJOR
METABOLITE -> PARENT
MINOR
Related Record Type Details
PARENT -> IMPURITY
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Related Record Type Details
ACTIVE MOIETY